Paper. Davis M, Farchione TR, Fischer BA et al.. The New England Journal of Medicine, 10 Sep 2026.
Eli Lilly agreed in July to acquire AtaiBeckley for $2.8 billion. In September, FDA officials set out the agency's updated framework for developing psychedelic drugs in the New England Journal of Medicine, building on its 2023 draft guidance.
How much weight it carries: News and policy, not research findings. (Industry, Policy)
Four FDA staff, including the psychiatry division director, set out the agency's psychedelic framework in NEJM.
It lands the same week JAMA ran both an Insights piece on psilocybin for depression and a patient-facing explainer, which is its own signal about where the audience now is.